Metformin is one of the safest and most widely studied diabetes medications available. Approved by the FDA in 1994, it has been used by tens of millions of people worldwide, and its safety record over three decades is strong. Like any medication, it comes with side effects and a few situations where it should be avoided, but for most people with type 2 diabetes, the benefits significantly outweigh the risks.
Common Side Effects
The most frequent complaints with metformin are digestive. About 20% of people experience some combination of diarrhea, nausea, bloating, or stomach pain, especially when first starting the medication. Diarrhea is the most common, affecting roughly 13% of users, followed by bloating at about 9% and nausea at around 6%.
These symptoms often improve over time. Starting at a low dose and gradually increasing it gives your gut a chance to adjust. An extended-release version of metformin also tends to be gentler on the stomach, though large-scale data hasn’t confirmed a dramatic difference. For most people, digestive side effects are a temporary nuisance rather than a reason to stop the medication.
Lactic Acidosis: The Rare but Serious Risk
Metformin carries a black box warning for lactic acidosis, a dangerous buildup of lactic acid in the blood. This sounds alarming, but the actual incidence is extremely low: roughly 9 cases per 100,000 person-years of use, or about 1 in 30,000 patients. For context, that makes it one of the rarest serious drug reactions you’ll encounter.
Lactic acidosis from metformin almost always occurs in people who have another major risk factor layered on top, most commonly severe kidney impairment. Healthy kidneys clear metformin efficiently, but when kidney function drops significantly, the drug can accumulate to dangerous levels. Heavy alcohol use is the other well-established trigger. Case reports suggest the risk climbs notably when alcohol intake exceeds 100 grams per day, which is roughly seven or more standard drinks. Moderate, occasional drinking is generally not a concern, but consistent heavy drinking while taking metformin is genuinely risky.
Kidney Function Thresholds
Because the kidneys are responsible for eliminating metformin, your kidney function determines whether the drug is safe for you. Doctors track this with a blood test called eGFR (estimated glomerular filtration rate), measured in mL/min. The FDA guidelines are straightforward:
- eGFR 45 or above: Metformin can be used safely at standard doses.
- eGFR 30 to 44: Starting metformin is not recommended. If you’re already taking it, the daily dose should be reduced to 1,000 mg or less.
- eGFR below 30: Metformin is contraindicated and should be stopped.
Routine blood work at your regular checkups typically includes kidney function, so this is something your prescribing doctor monitors over time.
Vitamin B12 Depletion Over Time
One underappreciated risk of long-term metformin use is vitamin B12 deficiency. Metformin reduces intestinal absorption of B12 in up to 30% of users, and 5 to 10% develop measurably low blood levels of the vitamin. Low levels can show up as early as three to four months after starting the drug, but symptomatic deficiency, which can cause nerve tingling, numbness, fatigue, and memory problems, typically takes 5 to 10 years to develop.
The risk increases with higher doses and longer duration of use. Since 2017, the American Diabetes Association has recommended regular B12 monitoring for people on metformin. If your levels drop, a simple B12 supplement corrects the problem. This is worth knowing about because B12 deficiency symptoms can mimic diabetic nerve damage, and the fix is easy once it’s identified.
Liver Disease and Metformin
There’s a common misconception that metformin is hard on the liver. In reality, metformin passes through the body without being metabolized by the liver at all. It has a short half-life of about five hours and is eliminated entirely through the kidneys. Liver impairment does not appear to change how the drug behaves in the body.
For people with stable, compensated liver cirrhosis, metformin is considered a promising treatment option because it improves insulin resistance, which is central to both type 2 diabetes and fatty liver disease. The historical caution around liver disease was driven by concern about lactic acidosis, but that risk is tied to kidney function, not liver function. As long as kidney function is adequate, liver disease alone is not a reason to avoid the drug.
Safety During Pregnancy
Metformin is increasingly used during pregnancy for gestational diabetes, and the safety data is reassuring for both mothers and babies. A large systematic review found that compared to insulin, metformin reduced the risk of neonatal hypoglycemia (dangerously low blood sugar in newborns) from about 14.8% to 10.1%. Babies born to mothers on metformin weighed slightly less on average, about 69 grams lighter, which in the context of gestational diabetes (where oversized babies are a concern) is generally considered favorable.
For mothers, metformin was associated with a significant reduction in preeclampsia risk compared to insulin, with no differences in rates of developing type 2 diabetes or insulin resistance after pregnancy. Long-term data on children exposed to metformin in the womb is still limited, though studies tracking kids to ages 7 to 9 have found no significant differences in body fat compared to those whose mothers used insulin.
Pausing Metformin for Medical Imaging
If you’re scheduled for a CT scan or other imaging that uses contrast dye, you may need to temporarily stop metformin. The concern is that contrast dye can temporarily stress the kidneys, and impaired kidney function plus metformin creates the conditions for lactic acidosis.
The protocol depends on your kidney function. If your eGFR is below 60, you should stop metformin at the time of contrast administration and wait at least 48 hours before restarting, and only after confirming your kidney function hasn’t changed. If your kidneys are healthy (eGFR above 60) and the scan uses a small amount of contrast, such as a brain CT, pausing metformin may not be necessary. For larger contrast volumes, like an abdominal CT or angiography, the 48-hour pause applies even with normal kidneys. Your imaging center will typically ask about metformin use and guide you through the process.
Cardiovascular Benefits Beyond Blood Sugar
Part of what makes metformin’s safety profile so favorable is that it doesn’t just lower blood sugar. It actively reduces cardiovascular risk. A meta-analysis of over one million patients found that metformin use was associated with a 33% reduction in all-cause mortality and a 19% reduction in cardiovascular mortality compared to other treatments. It also lowered the incidence of cardiovascular events like heart attacks and strokes by about 17% compared to sulfonylureas, an older class of diabetes drugs.
These aren’t small numbers. For a medication taken daily for years or decades, having built-in heart protection on top of glucose control is a meaningful safety advantage. It’s one of the main reasons metformin remains the first-line treatment for type 2 diabetes in virtually every major guideline worldwide, even as newer drug classes have entered the market.